Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.

Margherita RiminiValentina BurgioLorenzo AntonuzzoLorenza RimassaEster OnedaCaterina SoldàPasqua CitoGuglielmo NastiDaniele LavacchiValentina ZanusoMario Domenico RizzatoAlberto ZaniboniAlessandro OttaianoMara PersanoNoemi CornaraMario ScartozziStefano CascinuAndrea Casadei-Gardini

Published in: Therapeutic advances in medical oncology (2023)

The present update confirms the results of our previous real-world experience on the use of ivosidenib in IDH1-mutated CCA. Real-world evidence on larger numbers of patients is needed to confirm our findings.

Keyphrases

end stage renal disease
newly diagnosed
wild type
ejection fraction
chronic kidney disease
low grade
peritoneal dialysis
patient reported outcomes